MAP11: A Potential Drug Target Or Biomarker for Diseases (G23173)

Target Name: METAP1

NCBI ID: G23173

MAP11: A Potential Drug Target Or Biomarker for Diseases

Metap1 (MAP11_HUMAN) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The MAP11 gene is located on chromosome 11 and encodes a protein known as MAP11, which is a member of the transforming growth factor beta (TGF-β) superfamily.

MAP11 has been shown to play a role in several cellular processes that are important for normal development and function, including cell growth, differentiation, and survival. It has also been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of MAP11 is its role in the TGF-β signaling pathway. This pathway is a well-established framework for the regulation of cellular growth, differentiation, and survival, and is involved in the development and maintenance of tissues and organs during development. MAP11 is a key component of the TGF-β signaling pathway, and has been shown to play a critical role in its regulation.

In addition to its role in TGF-β signaling, MAP11 has also been shown to be involved in several other cellular processes that are important for normal development and function. For example, it has been shown to play a role in the regulation of cell adhesion, and is involved in the development and maintenance of tight junctions, which are important for the proper functioning of cells in the body.

The potential drug target or biomarker status of MAP11 is based on several factors. First, the MAP11 gene has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Second, MAP11 has been shown to play a role in the regulation of several cellular processes that are important for normal development and function. These findings suggest that MAP11 may be a promising drug target or biomarker for the treatment of these diseases.

Furthermore, several studies have also shown that inhibiting the activity of MAP11 has potential therapeutic benefits in these diseases. For example, studies have shown that inhibiting the activity of MAP11 has anti-tumor effects in cancer cells, and that it can also improve the cognitive function in neurodegenerative diseases.

In conclusion, MAP11 is a gene that has been shown to play a role in several cellular processes that are important for normal development and function, as well as the development and progression of several diseases. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapies for these diseases. Further research is needed to fully understand the role of MAP11 in these diseases and to develop effective treatments.

Protein Name: Methionyl Aminopeptidase 1

Functions: Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Required for normal progression through the cell cycle

More Common Targets